Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cosmetic Science
  4. Volume 1, Issue 2
  5. Article
Volume 1, Issue 2
  • ISSN: 2666-7797
  • E-ISSN: 2666-7800

Abstract

Psoriasis is a chronic inflammatory disease with clinical skin manifestations that affect adults and children. It can significantly negatively impact the physical, emotional, and psychosocial well-being of affected patients. It has a strong genetic component, but environmental factors such as infections can play an important role in the presentation of the disease. Patients suffering from a severe phase of this disease may have greater chances of other diseases like cardiovascular diseases, non-melanoma, and lymphoma. The present review majorly focuses on the hallmarks of different types of psoriasis, the evaluation of biomarkers to establish the severity and therapeutic response, and novel targeted therapies for managing psoriasis. Potential herbal extracts and bioactive for treating psoriasis are also highlighted here. A summary of pertinent, peer-reviewed English literature from databases like EBM, EMBASE and MEDLINE from 2010 to 2021 is used.

© 2022 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cosci/10.2174/2666779701666220623085521
2022-09-01
2025-01-01

  • From This Site

    /content/journals/cosci/10.2174/2666779701666220623085521
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SuY.H. FangJ.Y. Drug delivery and formulations for the topical treatment of psoriasis.Expert Opin. Drug Deliv.20085223524910.1517/17425247.5.2.235 18248321
     [Google Scholar]
  2. ParisiR. GriffithsC. AshcroftD. Systematic review of the incidence and prevalence of psoriasis: FC-11.Br. J. Dermatol.2011165166
     [Google Scholar]
  3. IbrahimG. WaxmanR. HelliwellP.S. The prevalence of psoriatic arthritis in people with psoriasis.Arthritis Rheum.200961101373137810.1002/art.24608 19790120
     [Google Scholar]
  4. KurdS.K. TroxelA.B. Crits-ChristophP. GelfandJ.M. The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study.Arch. Dermatol.20101468891895 20713823
     [Google Scholar]
  5. TejashriG. AmritaB. DarshanaJ. Cyclodextrin based nanosponges for pharmaceutical use: A review.Acta Parmaceutica.2013633335358
     [Google Scholar]
  6. SwaminathanS. VaviaP.R. TrottaF. TorneS. Formulation of betacyclodextrin based nanosponges of itraconazole.J. Incl. Phenom. Macrocycl. Chem.2007571-4899410.1007/s10847‑006‑9216‑9
     [Google Scholar]
  7. KruegerJ.G. BowcockA. Psoriasis pathophysiology: Current concepts of pathogenesis.Ann. Rheum. Dis.200564Suppl. 2ii30ii3610.1136/ard.2004.031120 15708932
     [Google Scholar]
  8. KeaneyT.C. KirsnerR.S. New insights into the mechanism of narrow-band UVB therapy for psoriasis.J. Invest. Dermatol.201013011253410.1038/jid.2010.287 20944634
     [Google Scholar]
  9. PietrzakA.T. ZalewskaA. ChodorowskaG. KrasowskaD. Michalak-StomaA. NockowskiP. OsemlakP. PaszkowskiT. RolińskiJ.M. Cytokines and anticytokines in psoriasis.Clin. Chim. Acta20083941-272110.1016/j.cca.2008.04.005 18445484
     [Google Scholar]
  10. HendersonD. Psoriasis severity linked to uncontrolled hypertension.Medscape Medical News2014
     [Google Scholar]
  11. TakeshitaJ. WangS. ShinD.B. MehtaN.N. KimmelS.E. MargolisD.J. TroxelA.B. GelfandJ.M. Effect of psoriasis severity on hypertension control: A population-based study in the United Kingdom.JAMA Dermatol.2015151216116910.1001/jamadermatol.2014.2094 25322196
     [Google Scholar]
  12. KellerJ.J. LinH.C. The effects of chronic periodontitis and its treatment on the subsequent risk of psoriasis.Br. J. Dermatol.201216761338134410.1111/j.1365‑2133.2012.11126.x 22755552
     [Google Scholar]
  13. FranzT.J. ParsellD.A. HalualaniR.M. HanniganJ.F. KalbachJ.P. HarkonenW.S. Betamethasone valerate foam 0.12%: A novel vehi-cle with enhanced delivery and efficacy.Int. J. Dermatol.199938862863210.1046/j.1365‑4362.1999.00782.x 10487457
     [Google Scholar]
  14. LomholtG. Prevalence of skin diseases in a population; a census study from the Faroe Islands.Dan. Med. Bull.19641117 14120983
     [Google Scholar]
  15. GreenA.C. Australian aborigines and psoriasis.Australas. J. Dermatol.1984251182410.1111/j.1440‑0960.1984.tb00618.x 6466238
     [Google Scholar]
  16. ConvitJ. Investigation of the incidence of psoriasis among Latin American Indians.Proceedings of the 13th Congress on DermatologyAmsterdam1962196
     [Google Scholar]
  17. OkhandiarR.P. BanerjeeB.N. Psoriasis in the tropics: An epidemiological survey.J. Indian Med. Assoc.196341550556 14088912
     [Google Scholar]
  18. BediT.R. Clinical profile of psoriasis in North India.Indian J. Dermatol. Venereol. Leprol.1995614202205 20952954
     [Google Scholar]
  19. KaurI. HandaS. KumarB. Natural history of psoriasis: A study from the Indian subcontinent.J. Dermatol.199724423023410.1111/j.1346‑8138.1997.tb02779.x9164063
     [Google Scholar]
  20. BoehnckeW.H. SchönM.P. Psoriasis.Lancet2015386999798399410.1016/S0140‑6736(14)61909‑7 26025581
     [Google Scholar]
  21. SternR.S. NijstenT. FeldmanS.R. MargolisD.J. RolstadT. Psoriasis is common, carries a substantial burden even when not exten-sive, and is associated with widespread treatment dissatisfaction.J. Investig. Dermatol. Symp. Proceed.2004913613910.1046/j.1087‑0024.2003.09102.x
     [Google Scholar]
  22. GelfandJ.M. GladmanD.D. MeaseP.J. SmithN. MargolisD.J. NijstenT. SternR.S. FeldmanS.R. RolstadT. Epidemiology of psoriatic arthritis in the population of the United States.J. Am. Acad. Dermatol.2005534573e110.1016/j.jaad.2005.03.046 16198775
     [Google Scholar]
  23. GelfandJ.M. FeldmanS.R. SternR.S. ThomasJ. RolstadT. MargolisD.J. Determinants of quality of life in patients with psoriasis: A study from the US population.J. Am. Acad. Dermatol.200451570470810.1016/j.jaad.2004.04.014 15523347
     [Google Scholar]
  24. MartinB.A. ChalmersR.J. TelferN.R. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?Arch. Dermatol.1996132671771810.1001/archderm.1996.038903001470328651734
     [Google Scholar]
  25. AsumalahtiK. AmeenM. SuomelaS. HagforsenE. MichaëlssonG. EvansJ. MunroM. VealC. AllenM. LemanJ. David Bur-den, A.; Kirby, B.; Connolly, M.; Griffiths, C.E.; Trembath, R.C.; Kere, J.; Saarialho-Kere, U.; Barker, J.N. Genetic analysis of PSORS1 dis-tinguishes guttate psoriasis and palmoplantar pustulosis.J. Invest. Dermatol.2003120462763210.1046/j.1523‑1747.2003.12094.x 12648227
     [Google Scholar]
  26. O’DohertyC.J. MacIntyreC. Palmoplantar pustulosis and smoking.Br. Med. J. (Clin. Res. Ed.)1985291649986186410.1136/bmj.291.6499.861 3931743
     [Google Scholar]
  27. AshokK. Fight psoriasis naturally through ayurveda.2016Available from: https://www.researchgate.net/profile/Ashok_Kumar422/publication/306914824/figure/fig2/AS:669671376306192@1536673506331/Figure-No1-Plaque psoriasis_W640.jpg
    [Google Scholar]
  28. AshokK. Fight psoriasis naturally through ayurveda.2016Available from: https://www.researchgate.net/profile/Ashok_Kumar422/publication/306914824/figure/fig6/AS:669671376306200@1536673506409/Figure-No5-Flexural-psoriasis_W640.jpg
    [Google Scholar]
  29. AshokK. Fight psoriasis naturally through ayurveda.2016Available fromhttps://www.researchgate.net/profile/Ashok_Kumar422/publication/306914824/figure/fig3/AS:669671376297997@1536673506347/Figure-No2-Pustular-psoriasis_W640.jpg
    [Google Scholar]
  30. AshokK. Fight psoriasis naturally through ayurveda.2016Available from:https://dermnetnz.org/assets/Uploads/scaly/ppps33__WatermarkedWyJXYXRlcm1hcmtlZCJd.jpg
    [Google Scholar]
  31. AshokK. Fight psoriasis naturally through ayurveda.2016Available fromhttps://www.researchgate.net/profile/Ashok_Kumar422/publication/306914824/figure/fig5/AS:669671376314382@15366735063 90/Figure-No4-Guttate-Psoriasis_W640.jpg
    [Google Scholar]
  32. AshokK. Fight psoriasis naturally through ayurveda.2016Available fromhttps://www.verywellhealth.com/thmb/t1ppX4QhayIb74AMq4 Mrav4BKjo=/700x0/filters:no_upscale():max_bytes(150000):strip_ icc():format(webp)/psorEderm4b8b084609064557aaa092b5614bf 579.jpg
    [Google Scholar]
  33. AshokK. Fight psoriasis naturally through ayurveda.2016Available fromhttps://www.researchgate.net/profile/Ashok_Kumar422/publication/306914824/figure/fig4/AS:669671376306198@15366735 06361/Figure-No3-Nail-psoriasis_W640.jpg
    [Google Scholar]
  34. AlmeidaA.J. SoutoE. Solid lipid nanoparticles as a drug delivery system for peptides and proteins.Adv. Drug Deliv. Rev.200759647849010.1016/j.addr.2007.04.007 17543416
     [Google Scholar]
  35. MorgantiP. RuoccoE. WolfR. RuoccoV. Percutaneous absorption and delivery systems.Clin. Dermatol.200119448950110.1016/S0738‑081X(01)00183‑3 11535394
     [Google Scholar]
  36. OkaA. TamiyaG. TomizawaM. OtaM. KatsuyamaY. MakinoS. ShiinaT. YoshitomeM. IizukaM. SasaoY. IwashitaK. KawakuboY. SugaiJ. OzawaA. OhkidoM. KimuraM. BahramS. InokoH. Association analysis using refined microsatellite mark-ers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene.Hum. Mol. Genet.19998122165217010.1093/hmg/8.12.2165 10545595
     [Google Scholar]
  37. PappK.A. KruegerJ.G. FeldmanS.R. LangleyR.G. ThaciD. ToriiH. TyringS. WolkR. GardnerA. MebusC. TanH. LuoY. GuptaP. MallbrisL. TatulychS. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term ef-ficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.J. Am. Acad. Dermatol.201674584185010.1016/j.jaad.2016.01.013 26899199
     [Google Scholar]
  38. BjørneboeA. SmithA.K. BjørneboeG.E. ThuneP.O. DrevonC.A. Effect of dietary supplementation with n-3 fatty acids on clinical manifestations of psoriasis.Br. J. Dermatol.19881181778310.1111/j.1365‑2133.1988.tb01753.x 2829958
     [Google Scholar]
  39. CalderP.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases.Am. J. Clin. Nutr.2006836Suppl.1505S1519S10.1093/ajcn/83.6.1505S 16841861
     [Google Scholar]
  40. BayliffeA.I. BrigandiR.A. WilkinsH.J. LevickM.P. Emerging therapeutic targets in psoriasis.Curr. Opin. Pharmacol.20044330631010.1016/j.coph.2004.02.003 15140425
     [Google Scholar]
  41. LebwohlM. Future psoriasis therapy.Dermatol. Clin.199513491592310.1016/S0733‑8635(18)30054‑8 8785895
     [Google Scholar]
  42. MenterA. KormanN.J. ElmetsC.A. FeldmanS.R. GelfandJ.M. GordonK.B. GottliebA. KooJ.Y. LebwohlM. LeonardiC.L. LimH.W. Van VoorheesA.S. BeutnerK.R. RyanC. BhushanR. Guidelines of care for the management of psoriasis and psoriatic ar-thritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based con-clusions.J. Am. Acad. Dermatol.201165113717410.1016/j.jaad.2010.11.055 21306785
     [Google Scholar]
  43. KragballeK. GjertsenB.T. De HoopD. KarlsmarkT. van de KerkhofP.C. LarköO. NieboerC. Roed-PetersenJ. StrandA. TikjøbG. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris.Lancet1991337873519319610.1016/0140‑6736(91)92157‑W 1670840
     [Google Scholar]
  44. LebwohlM. AliS. Treatment of psoriasis. Part 1. Topical therapy and phototherapy.J. Am. Acad. Dermatol.200145448749810.1067/mjd.2001.117046 11568737
     [Google Scholar]
  45. KragballeK. Treatment of psoriasis with calcipotriol and other vitamin D analogues.J. Am. Acad. Dermatol.1992276 Pt 11001100810.1016/0190‑9622(92)70302‑V 1479078
     [Google Scholar]
  46. GrantW.B. HolickM.F. Benefits and requirements of vitamin D for optimal health: A review.Altern. Med. Rev.200510294111 15989379
     [Google Scholar]
  47. SchmittJ. RosumeckS. ThomaschewskiG. SporbeckB. HaufeE. NastA. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.Br. J. Dermatol.2014170227430310.1111/bjd.12663 24131260
     [Google Scholar]
  48. NastA. JacobsA. RosumeckS. WernerR.N. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.J. Invest. Dermatol.2015135112641264810.1038/jid.2015.206 26046458
     [Google Scholar]
  49. BuccheriL. KatchenB.R. KarterA.J. CohenS.R. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection.Arch. Dermatol.1997133671171510.1001/archderm.1997.03890420043005 9197824
     [Google Scholar]
  50. StroberB.E. SiuK. MenonK. Conventional systemic agents for psoriasis. A systematic review.J. Rheumatol.200633714421446 16724368
     [Google Scholar]
  51. HoV.C. GriffithsC. AlbrechtG. VanaclochaF. León-DorantesG. AtakanN. ReitamoS. JohannessonA. MØRK, N.; Clarke, P.; Pfister, P. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: A 1-year multicentre, random-ized study.Br. J. Dermatol.1999141228329110.1046/j.1365‑2133.1999.02977.x 10468801
     [Google Scholar]
  52. MukherjeeS. DateA. PatravaleV. KortingH.C. RoederA. WeindlG. Retinoids in the treatment of skin aging: An overview of clinical efficacy and safety.Clin. Interv. Aging20061432734810.2147/ciia.2006.1.4.327 18046911
     [Google Scholar]
  53. BokarewaM. NagaevI. DahlbergL. SmithU. TarkowskiA. Resistin, an adipokine with potent proinflammatory properties.J. Immunol.200517495789579510.4049/jimmunol.174.9.5789 15843582
     [Google Scholar]
  54. JohnstonA. ArnadottirS. GudjonssonJ.E. AphaleA. SigmarsdottirA.A. GunnarssonS.I. SteinssonJ.T. ElderJ.T. ValdimarssonH. Obesity in psoriasis: Leptin and resistin as mediators of cutaneous inflammation.Br. J. Dermatol.2008159234235010.1111/j.1365‑2133.2008.08655.x 18547319
     [Google Scholar]
  55. DavisR.H. ParkerW.L. SamsonR.T. MurdochD.P. Isolation of a stimulatory system in an Aloe extract.J. Am. Podiatr. Med. Assoc.199181947347810.7547/87507315‑81‑9‑473 1748962
     [Google Scholar]
  56. TabassumN. HamdaniM. Plants used to treat skin diseases.Pharmacogn. Rev.2014815526010.4103/0973‑7847.125531 24600196
     [Google Scholar]
  57. ParkS.N. LeeM.H. KimS.J. YuE.R. Preparation of quercetin and rutin-loaded ceramide liposomes and drug-releasing effect in lipo-some-in-hydrogel complex system.Biochem. Biophys. Res. Commun.2013435336136610.1016/j.bbrc.2013.04.093 23669037
     [Google Scholar]
  58. Shams-GhahfarokhiM. ShokoohamiriM.R. AmirrajabN. MoghadasiB. GhajariA. ZeiniF. SadeghiG. Razzaghi-AbyanehM. In vitro antifungal activities of Allium cepa, Allium sativum and ketoconazole against some pathogenic yeasts and dermatophytes.Fitoterapia200677432132310.1016/j.fitote.2006.03.014 16690223
     [Google Scholar]
  59. DasI. SahaT. Effect of garlic on lipid peroxidation and antioxidation enzymes in DMBA-induced skin carcinoma.Nutrition200925445947110.1016/j.nut.2008.10.014 19084378
     [Google Scholar]
  60. Debug Lies NewsAvailable from: http://debuglies.com/wp-content/uploads/2018/10/Psoriasis-symptoms.-768x372.png
    [Google Scholar]
  61. Very well Health. Available from https://www.verywellhealth.com/thmb/OTlq1t6DTOsmixRhfbUqwiL5TW4=/768x0/filters:no_upscale():max_bytes(150000):strip_icc():format(webp)/aloe-vera-509144858-5a242f7389eacc0037c5c1e0.jpg
    [Google Scholar]
  62. Data + Empathy = Patient Impact. Healthline. Available from https://www.healthline.com/hlcmsresource/images/imce/psoriatic-arthritis-natural-remedies_thumb.jpg
    [Google Scholar]
  63. All my Chefs.Available from: https://www.allmychefs.com/images/1013/370-274/ffffff/fotolia_52283514_subscription_xl-copy. jpg?poix=50&poiy=50
    [Google Scholar]
  64. Stylecraze.Available from: https://cdn2.stylecraze.com/wp-content/uploads/2013/08/995_139346633.jpg
    [Google Scholar]
  65. SIBO Survivor Available from https://sibosurvivor.com/wp-content/uploads/2017/08/AllicinGarlic.jpg
  66. PandeyK. An overview on promising nanotechnological approaches for the treatment of psoriasis.Recent Patents. Nanotechnol.2020142102118
     [Google Scholar]
  67. NimishaD.A. RizviD.A. FatimaZ. Neema; Kaur, C.D. Antipsoriatic and anti-inflammatory studies of Berberis aristata extract loaded nanovesicular gels.Pharmacogn. Mag.20171351Suppl. 3S587S59410.4103/pm.pm_210_17 29142419
     [Google Scholar]
  68. Keep Fit KingdomAvailable from: https://keepfitkingdom.com/wp-content/uploads/2017/08/Top-5-Health-Benefits-of-Milk-Thistle-Seeds-Keep-Fit-Kingdom-770x472-1.jpg
    [Google Scholar]
  69. Immunotrax. Psoriasis Relief.Available from https://www.immunotrax.com/en/product/psoriasis-relief/
    [Google Scholar]
  70. Flipkart. Psorvin herbal oil for psoriasis Available from: https://www.flipkart.com/psorvin-herbal-oil-psoriasis-2x30-ml-pack-2-each-30-ml/p/itmfb08bef16c782
    [Google Scholar]
  71. Mandanapalas. Psorolin cream.Available from https://www.madanapalas.com/psorolin-ointment-p-815.html
    [Google Scholar]
  72. Kerala Ayurveda. Winsoria Oil. Available from, https://www.keralaayurveda.biz/product/winsoria-oil
    [Google Scholar]
  73. Shopri. Available from https://www.shopri.in/sisairosp-psoriasis-lotion-100-ml-pack-2/s/bstfff8f62cyp75ugb
    [Google Scholar]
  74. Pharmayush. PsoreaseAvailable from: https://pharmayush.com/dr-stanley-s-psorease.html
    [Google Scholar]
  75. DubertretL. MrowietzU. RankiA. van de KerkhofP.C. ChimentiS. LottiT. SchäferG. European patient perspectives on the im-pact of psoriasis: The EUROPSO patient membership survey.Br. J. Dermatol.2006155472973610.1111/j.1365‑2133.2006.07405.x 16965422
     [Google Scholar]
  76. GoedkoopA.Y. KraanM.C. TeunissenM.B. PicavetD.I. de RieM.A. BosJ.D. TakP.P. Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.Ann. Rheum. Dis.200463776977310.1136/ard.2003.018085 15194570
     [Google Scholar]
  77. RoenigkH.H.Jr AuerbachR. MaibachH. WeinsteinG. LebwohlM. Methotrexate in psoriasis: Consensus conference.J. Am. Acad. Dermatol.199838347848510.1016/S0190‑9622(98)70508‑0 9520032
     [Google Scholar]
  78. Janssen.Available from https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf
    [Google Scholar]
  79. Available from: https://reference.medscape.com/drug/amevive-alefacept-343188
  80. van der FitsL. MouritsS. VoermanJ.S. KantM. BoonL. LamanJ.D. CornelissenF. MusA.M. FlorenciaE. PrensE.P. Lub-bertsE. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.J. Immunol.200918295836584510.4049/jimmunol.0802999 19380832
     [Google Scholar]
  81. ShahP.P. DesaiP.R. PatelA.R. SinghM.S. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs.Biomaterials20123351607161710.1016/j.biomaterials.2011.11.011 22118820
     [Google Scholar]
  82. BoehnckeW.H. MenterA. Burden of disease: Psoriasis and psoriatic arthritis.Am. J. Clin. Dermatol.201314537738810.1007/s40257‑013‑0032‑x 23771648
     [Google Scholar]
  83. KirkhamB.W. KavanaughA. ReichK. Interleukin-17A: A unique pathway in immune-mediated diseases: Psoriasis, psoriatic arthritis and rheumatoid arthritis.Immunology2014141213314210.1111/imm.12142 23819583
     [Google Scholar]
  84. ChangH.N. PangJ.H. YangS.H. HungC.F. ChiangC.H. LinT.Y. LinY.K. Inhibitory effect of indigo naturalis on tumor necrosis factor-α-induced vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells.Molecules20101596423643510.3390/molecules15096423 20877233
     [Google Scholar]
  85. Martínez-NavarroF.J. Martínez-MenchónT. MuleroV. Galindo-VillegasJ. Models of human psoriasis: Zebrafish the newly appointed player.Dev. Comp. Immunol.201997768710.1016/j.dci.2019.03.018 30953679
     [Google Scholar]
  86. WebbA.E. DrieverW. KimelmanD. psoriasis regulates epidermal development in zebrafish.Dev. Dyn.200823741153116410.1002/dvdy.21509 18351656
     [Google Scholar]
  87. BoehnckeW.H. SchönM.P. Animal models of psoriasis.Clin. Dermatol.200725659660510.1016/j.clindermatol.2007.08.014 18021898
     [Google Scholar]
  88. SundbergJ.P. BoggessD. SundbergB.A. BeamerW.G. ShultzL.D. Epidermal dendritic cell populations in the flaky skin mutant mouse.Immunol. Invest.199322538940110.3109/08820139309063417 8406628
     [Google Scholar]
  89. NakagumaH. KambaraT. YamamotoT. Rat ultraviolet ray B photodermatitis: An experimental model of psoriasis vulgaris.Int. J. Exp. Pathol.19957616573 7734340
     [Google Scholar]
  90. SrivastavaN. Zeeshan, Fatima; Chanchal, Deep Kaur; Dilshad, Ali Rizvi Berberine chloride dihydrate enthused nanovesicles for the man-agement of dermatitis nanovesicles for dermatitis.Nanosci. Nanotechnol. Asia202010110.2174/2210681210666200313123550
     [Google Scholar]
  91. FatimaZ. KaurC.D. A review on potential of novel vesicular carriers for carrying herbal drugs in the treatment of dermatological disor-ders.J. Atoms Mol.201663987
     [Google Scholar]
  92. VincentN. RamyaD.D. VedhaH.B. Progress in psoriasis therapy via novel drug delivery systems.Dermatol. Rep.201461545110.4081/dr.2014.5451 25386329
     [Google Scholar]
  93. NasrM. MansourS. MortadaN.D. ElshamyA.A. Vesicular aceclofenac systems: A comparative study between liposomes and nio-somes.J. Microencapsul.200825749951210.1080/02652040802055411 18608811
     [Google Scholar]
  94. LasicD.D. Novel applications of liposomes.Trends Biotechnol.199816730732110.1016/S0167‑7799(98)01220‑7 9675915
     [Google Scholar]
  95. NasrM. MansourS. MortadaN.D. El ShamyA.A. Lipospheres as carriers for topical delivery of aceclofenac: Preparation, characteriza-tion and in vivo evaluation.AAPS PharmSciTech20089115416210.1208/s12249‑007‑9028‑2 18446476
     [Google Scholar]
  96. SrisukP. ThongnopnuaP. RaktanonchaiU. KanokpanontS. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment.Int. J. Pharm.2012427242643410.1016/j.ijpharm.2012.01.045 22310459
     [Google Scholar]
  97. AbolmaaliS.S. TamaddonA.M. FarvadiF.S. DaneshamuzS. MoghimiH. Pharmaceutical nanoemulsions and their potential topical and transdermal applications.Iranian J. Pharm. Sci.201173139150
     [Google Scholar]
  98. JoshiM. PatravaleV. Nanostructured lipid carrier (NLC) based gel of celecoxib. International journal of pharmaceutics. 2008 Jan 4;346(1-2):124-32. Avramoff A, Khan W, Ezra A, Elgart A, Hoffman A, Domb AJ. Cyclosporin pro-dispersion liposphere formulation.J. Control. Release20121602401406 22227025
     [Google Scholar]
  99. AbdelbaryA.A. AbouGhalyM.H. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoria-sis: Application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study.Int. J. Pharm.20154851-223524310.1016/j.ijpharm.2015.03.020 25773359
     [Google Scholar]
  100. BathejaP. SheihetL. KohnJ. SingerA.J. Michniak-KohnB. Topical drug delivery by a polymeric nanosphere gel: Formulation opti-mization and in vitro and in vivo skin distribution studies.J. Control. Release2011149215916710.1016/j.jconrel.2010.10.005 20950659
     [Google Scholar]
  101. KilfoyleB.E. Tyrosine-derived nanoparticles for the topical treatment of psoriasis.Rutgers The State University of New Jersey-New Bruns-wick2011
     [Google Scholar]
  102. NasrM. Abdel-HamidS. Lipid based nanocapsules: A multitude of biomedical applications.Curr. Pharm. Biotechnol.201516432233210.2174/138920101604150218103555 25543690
     [Google Scholar]
  103. SavianA.L. RodriguesD. WeberJ. RibeiroR.F. MottaM.H. SchaffazickS.R. AdamsA.I. de AndradeD.F. BeckR.C. da SilvaC.B. Dithranol-loaded lipid-core nanocapsules improve the photostability and reduce the in vitro irritation potential of this drug.Mater. Sci. Eng. C201546697610.1016/j.msec.2014.10.011 25491961
     [Google Scholar]
  104. CevcG. BlumeG. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force.Biochim. Biophys. Acta19921104122623210.1016/0005‑2736(92)90154‑E 1550849
     [Google Scholar]
  105. ChaudharyH. KohliK. KumarV. Nano-transfersomes as a novel carrier for transdermal delivery.Int. J. Pharm.2013454136738010.1016/j.ijpharm.2013.07.031 23871739
     [Google Scholar]
  106. ElsayedM.M. AbdallahO.Y. NaggarV.F. KhalafallahN.M. Lipid vesicles for skin delivery of drugs: Reviewing three decades of re-search.Int. J. Pharm.20073321-211610.1016/j.ijpharm.2006.12.005 17222523
     [Google Scholar]
  107. GuptaM. AgrawalU. VyasS.P. Nanocarrier-based topical drug delivery for the treatment of skin diseases.Expert Opin. Drug Deliv.20129778380410.1517/17425247.2012.686490 22559240
     [Google Scholar]
  108. CevcG. SchätzleinA. BlumeG. Transdermal drug carriers: Basic properties, optimization and transfer efficiency in the case of epicuta-neously applied peptides.J. Control. Release1995361-231610.1016/0168‑3659(95)00056‑E
     [Google Scholar]
  109. El ZaafaranyG.M. AwadG.A. HolayelS.M. MortadaN.D. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery.Int. J. Pharm.20103971-216417210.1016/j.ijpharm.2010.06.034 20599487
     [Google Scholar]
  110. MalakarJ. SenS.O. NayakA.K. SenK.K. Formulation, optimization and evaluation of transferosomal gel for transdermal insulin deliv-ery.Saudi Pharm. J.201220435536310.1016/j.jsps.2012.02.001 23960810
     [Google Scholar]
  111. TrottaM. PeiraE. CarlottiM.E. GallarateM. Deformable liposomes for dermal administration of methotrexate.Int. J. Pharm.20042701-211912510.1016/j.ijpharm.2003.10.006 14726128
     [Google Scholar]
  112. BhatiaA. SinghB. WadhwaS. RazaK. KatareO.P. Novel phospholipid-based topical formulations of tamoxifen: Evaluation for an-tipsoriatic activity using mouse-tail model.Pharm. Dev. Technol.201419216016310.3109/10837450.2013.763260 23369039
     [Google Scholar]
  113. BseisoE.A. NasrM. SammourO. Abd El GawadN.A. Recent advances in topical formulation carriers of antifungal agents.Indian J. Dermatol. Venereol. Leprol.201581545746310.4103/0378‑6323.162328 26261140
     [Google Scholar]
  114. NayakN. SomannaP. PatilA.B. RadhakrishnanA. Progress in novel ultradeformable vesicular drug carrier in the topical and transder-mal treatment of psoriasis.Ther. Deliv.2020111280781910.4155/tde‑2020‑0081 33267650
     [Google Scholar]
  115. FatimaZ. Formulation and performance evaluation of Berberis aristata extract loaded ethosomal gel. Asian J Pharm2017113Available from: https://doi.org/10.22377/ajp.v11i03.1401
    [Google Scholar]
  116. PrasanthiD. LakshmiP.K. Vesicles-mechanism of transdermal permeation: A review.Asian J. Pharm. Clin. Res.2012511825
     [Google Scholar]
  117. ChourasiaM.K. KangL. ChanS.Y. Nanosized ethosomes bearing ketoprofen for improved transdermal delivery.Results Pharma Sci.201111606710.1016/j.rinphs.2011.10.002 25755983
     [Google Scholar]
  118. ZhangY.T. ShenL.N. WuZ.H. ZhaoJ.H. FengN.P. Comparison of ethosomes and liposomes for skin delivery of psoralen for psori-asis therapy.Int. J. Pharm.20144711-244945210.1016/j.ijpharm.2014.06.001 24907596
     [Google Scholar]
  119. FangY.P. HuangY.B. WuP.C. TsaiY.H. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior.Eur. J. Pharm. Biopharm.200973339139810.1016/j.ejpb.2009.07.011 19660544
     [Google Scholar]
  120. KumariS. PathakK. Cavamax W7 composite psoralen ethosomal gel versus cavamax W7 psoralen solid complex gel for topical delivery: A comparative evaluation.Int. J. Pharm. Investig.20133417118210.4103/2230‑973X.121284 24350036
     [Google Scholar]
  121. CroyS.R. KwonG.S. Polymeric micelles for drug delivery.Curr. Pharm. Des.200612364669468410.2174/138161206779026245 17168771
     [Google Scholar]
  122. LaptevaM. MondonK. MöllerM. GurnyR. KaliaY.N. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: A targeted approach for the treatment of psoriasis.Mol. Pharm.20141192989300110.1021/mp400639e 25057896
     [Google Scholar]
  123. SingkaG.S. SamahN.A. ZulfakarM.H. YurdasiperA. HeardC.M. Enhanced topical delivery and anti-inflammatory activity of metho-trexate from an activated nanogel.Eur. J. Pharm. Biopharm.201076227528110.1016/j.ejpb.2010.06.014 20600884
     [Google Scholar]
  124. HathoutR.M. NasrM. Transdermal delivery of betahistine hydrochloride using microemulsions: Physical characterization, biophysical assessment, confocal imaging and permeation studies.Colloids Surf. B Biointerfaces201311025426010.1016/j.colsurfb.2013.05.007 23732802
     [Google Scholar]
  125. SharmaK. BediN. Microemulsion based hydrogel of mycophenolate mofetil for the treatment of psoriasis.Curr. Trends Biotechnol. Pharm.20148359371
     [Google Scholar]
  126. KimI.S. KimS.H. Development of a polymeric nanoparticulate drug delivery system. in vitro characterization of nanoparticles based on sugar-containing conjugates.Int. J. Pharm.20022451-2677310.1016/S0378‑5173(02)00336‑8 12270243
     [Google Scholar]
  127. JacobS. NairA.B. ShahJ. Emerging role of nanosuspensions in drug delivery systems.Biomater. Res.2020241310.1186/s40824‑020‑0184‑8 31969986
     [Google Scholar]
  128. YangF. KamiyaN. GotoM. Transdermal delivery of the anti-rheumatic agent methotrexate using a solid-in-oil nanocarrier.Eur. J. Pharm. Biopharm.201282115816310.1016/j.ejpb.2012.05.016 22713517
     [Google Scholar]
  129. GholapA.D. BorudeS.S. MahajanA.M. GholapM.A. Aquasomes: A potential drug delivery carrier.Pharmacol Online.20113230237
     [Google Scholar]
  130. NanjwadeB.K. HiremathG.M. Aquasome Based Drug Delivery.SaarbruckenLap Lambert Academic Publishing GmbH & Co2012
     [Google Scholar]
  131. NaldiL. PeliL. ParazziniF. CarrelC.F. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: Results of a case-control study.J. Am. Acad. Dermatol.200144343343810.1067/mjd.2001.110876 11209111
     [Google Scholar]
  132. PettittD. PlotnickM. MillerL.S. BerlinJ.A. WangY. ZhaoJ. GisondiP. SinvhalR. ArmstrongA.W. Letter to the editor concern-ing the article: Comparative safety and benefit-risk profile of biologics and oral treatments for moderate-to-severe plaque psoriasis: A net-work meta-analysis of clinical trial data.J. Am. Acad. Dermatol.2021855e305e30610.1016/j.jaad.2021.05.068 34311042
     [Google Scholar]
  133. CamelaE. FabbrociniG. CinelliE. LauroW. MegnaM. Biologic therapies, psoriasis, and COVID-19: Our experience at the psoriasis unit of the university of naples federico II.Dermatology202123711314 33296899
     [Google Scholar]
/content/journals/cosci/10.2174/2666779701666220623085521
Loading
Nanoformulations Enabled Possible Solutions for the Management of Psoriasis
Curr. Cosm. Sci. 1, e230622206307 (2022); https://doi.org/10.2174/2666779701666220623085521
/content/journals/cosci/10.2174/2666779701666220623085521
/content/journals/cosci/10.2174/2666779701666220623085521
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): biomarker; databases; inflammatory disease; Psoriasis; psychosocial; targeted therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test